In this article, we present four focused research insights highlighting the broad and clinically relevant potential of curcumin, from metabolic control in type 2 diabetes and support in bacterial vaginosis, to exercise-related muscle recovery and musculoskeletal health in postmenopausal women.
The following summaries are based on expert research briefings originally shared in the Vitamin Professor Newsletter by Dr. Gene Bruno.
Curcumin for type 2 diabetes
This randomized, double-blind, placebo-controlled trial[3] assessed the efficacy of curcumin (from Curcuma longa) for improving type 2 diabetes (T2DM) in subjects (n = 272) with criteria for type 2 diabetes. All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. Results were that after 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05) and HbA1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (i.e., a hormone that helps regulate glucose and fatty acid levels,14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (i.e., a hormone that helps regulate body weight, 9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34; P = 0.001). In conclusion, a 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.
Curcumin for bacterial vaginosis
A double-blind randomized clinical trial[3] was conducted to compare the efficacy of 40 mg curcumin (nano micelle pill) and 500 mg metronidazole in the treatment of bacterial vaginosis (BV) in 100 married women aged 18-49 who were not pregnant. Subjects were randomly allocated to the intervention or control groups. Both groups were instructed to take their respective medications every 12 h for seven days. Subsequently, two weeks following the treatment, the efficacy of the treatment was assessed utilizing Amsel’s clinical and paraclinical criteria. The data was analyzed using the intention-to-treat (ITT) approach. The clinical (discharge P = 0.01; whiff test P = 0.03 and pH P = 0.03) and paraclinical variables of Amsel criteria (clue cells P = 0.02) showed significant differences between groups. The curcumin consumer group exhibited a complete improvement rate of 82%, in contrast to the metronidazole group which had a rate of 42% two weeks after intervention. This study found curcumin to have comparable efficacy to metronidazole in treating BV while demonstrating superior effectiveness and fewer adverse effects in alleviating symptoms.
Dose-dependent effect of curcumin on muscle recovery
This study[iii] investigated the effects of two dosages (750 mg and 1500 mg) of hydrolyzed curcumin on physiological recovery following exercise-induced muscle damage (EIMD). In a randomized, placebo-controlled, double-blind design, 34 recreationally active males (27 ± 6 years; 180 ± 7.3 cm; 82 ± 11.3 kg) were assigned to three groups: PLA (2 × 750-mg/day placebo), LOW (1 × 750-mg/day curcumin + 1 × 750-mg/day placebo), and HIGH (2 × 750-mg/day curcumin). Supplements were delivered in 15 mL gel sachets over 7 days, starting 48 h before EIMD. The EIMD protocol involved 8 sets of 10 repetitions at 110% of one-repetition maximum on the leg press, with 5-s eccentric phases and assisted concentric phases, targeting the quadriceps. Recovery was assessed pre, post, 24, 48, and 72 h post-EIMD via the Free Oxygen Radical Test (FORT), creatine kinase (CK), interleukin-6 (IL-6), isokinetic peak power, and a muscle endurance test (sustained isometric contraction at 50% peak torque). The HIGH group showed significantly greater reductions in pain, CK, FORT, and IL-6 (p < 0.05), but slower muscle endurance recovery at 24 h compared to LOW. Findings suggest a dose-response effect, with higher curcumin doses improving biochemical recovery but potentially impairing performance recovery.
Curcumin for musculoskeletal health and fatigue in postmenopausal women
Considering the proven anti-inflammatory effects of curcumin, a parallel-group, double-blind, randomized placebo-controlled superiority trial[ii] was conducted to investigate the effect of curcumin supplementation on fatigue and musculoskeletal health (primary outcomes) and depression and its side effects (secondary outcomes) in 74 postmenopausal women. They were randomly assigned to receive either 500 mg curcumin capsules (intervention group, n=37) or identical placebo capsules (control group, n=37) twice daily for 8 weeks. Data were collected using the questionnaires of demographic characteristics, short form of the perimenopausal fatigue scale, musculoskeletal health, Beck Depression Inventory (BDI-13) and the side effects checklist. Independent t, ANCOVA and Mann-Whitney U tests were used to compare the results between the two groups. Results were that 33 women in the curcumin group and 31 in the placebo group completed the study and were included in the final analysis. The curcumin group showed a statistically significant improvement in musculoskeletal health (mean difference (p<0.001); the observed mean difference fell just short of the MCID (the minimum clinically important difference), yet remarkably close. A statistically significant decrease in fatigue scale (p<0.001) was observed compared with the placebo group; there is no MCID validated for this scale. No significant difference was observed between the groups in terms of depression (p=0.245); there is no universally accepted MCID specifically validated for the BDI-II 13-item version. Some participants reported side effects including stomachache and headache, leading to dropout. In conclusion, 8-week supplementation with curcumin was more effective than placebo at improving musculoskeletal health and reducing fatigue score in postmenopausal women.
Read more on Curcumin here:
Curcumin: The Golden Spice Shining a Light on Chronic Disease Management
The four short research highlights presented in this article are adapted from recent editions of the Vitamin Professor Newsletter by Dr. Gene Bruno. His curated updates translate current scientific findings into practical, formulation-relevant knowledge for the nutraceutical and health-ingredient community.
To stay connected with future insights and research updates, readers are encouraged to explore the Vitamin Professor Newsletters on LinkedIn:
Dr. Gene Bruno, DBM, MS, RH(AHG) is a 47-year veteran of the dietary supplement industry, and for 20 of those years he served as Professor of Nutraceutical Science at Huntington University of Health Sciences. He now serves as Chief Scientific Officer for Nutraland USA. As “The Vitamin Professor™”, Gene will share the most recent research on nutraceuticals in this free bimonthly newsletter. Make sure to subscribe.
